Advanced search
Publication Cover
Leukemia & Lymphoma Volume 48, 2007 - Issue 12
Submit an article Journal homepage
770
Views
74
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features

Deborah A. Bowen Mayo Clinic College of Medicine, Rochester, Minnesota, USA
,
Timothy G. Call Mayo Clinic College of Medicine, Rochester, Minnesota, USA
,
Greg D. Jenkins Mayo Clinic College of Medicine, Rochester, Minnesota, USA
,
Clive S. Zent Mayo Clinic College of Medicine, Rochester, Minnesota, USA
,
Susan M. Schwager Mayo Clinic College of Medicine, Rochester, Minnesota, USA
,
Daniel L. Van Dyke Mayo Clinic College of Medicine, Rochester, Minnesota, USA
,
Diane F. Jelinek Mayo Clinic College of Medicine, Rochester, Minnesota, USA
,
Neil E. Kay Mayo Clinic College of Medicine, Rochester, Minnesota, USA
&
Tait D. Shanafelt Mayo Clinic College of Medicine, Rochester, Minnesota, USACorrespondence[email protected]
 show all
Pages 2412-2417 | Received 05 Sep 2007, Accepted 02 Oct 2007, Published online: 01 Jul 2009

Citations (74)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (19)

Constantine S. Tam & Stephan Stilgenbauer. (2015) How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?. Leukemia & Lymphoma 56:3, pages 587-593.
Read now
Tadeusz Robak. (2014) Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art. Expert Review of Hematology 7:6, pages 841-857.
Read now
Niamh Coleman, Philip Thomas Murphy, Patrick Thornton & John Quinn. (2013) Pure red cell aplasia complicating chronic lymphocytic leukemia: rapid response to high-dose methylprednisolone and rituximab. Leukemia & Lymphoma 54:10, pages 2333-2335.
Read now
Preetesh Jain & Susan O'Brien. (2013) Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia. Expert Opinion on Biological Therapy 13:2, pages 169-182.
Read now
Tadeusz Robak, Pawel Robak & Piotr Smolewski. (2012) The evaluation and optimal use of rituximab in lymphoid malignancies. Blood and Lymphatic Cancer: Targets and Therapy 2, pages 1-16.
Read now
Lukáš Smolej. (2012) The role of high-dose corticosteroids in the treatment of chronic lymphocytic leukemia. Expert Opinion on Investigational Drugs 21:7, pages 1009-1017.
Read now
Tadeusz Robak. (2012) Rituximab for chronic lymphocytic leukemia. Expert Opinion on Biological Therapy 12:4, pages 503-515.
Read now
Clive S. Zent & Neil E. Kay. (2011) Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach. Leukemia & Lymphoma 52:8, pages 1425-1434.
Read now
Regina Pileckyte, Mindaugas Jurgutis, Vilma Valceckiene, Mindaugas Stoskus, Egle Gineikiene, Jurgita Sejoniene, Andrius Degulys, Tadas Zvirblis & Laimonas Griskevicius. (2011) Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia. Leukemia & Lymphoma 52:6, pages 1055-1065.
Read now
Alessandra Tedeschi, Eleonora Vismara, Francesca Ricci, Enrica Morra & Marco Montillo. (2010) The spectrum of use of rituximab in chronic lymphocytic leukemia. OncoTargets and Therapy 3, pages 227-246.
Read now
Aref Al-Kali, William Wierda, Michael Keating & Susan O’Brien. (2010) Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL). Journal of Blood Medicine 1, pages 115-122.
Read now
Tadeusz Robak, Ewa Lech-Maranda & Pawel Robak. (2010) Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia. Expert Review of Anticancer Therapy 10:10, pages 1529-1543.
Read now
Tait D. Shanafelt, Kari G. Rabe, Neil E. Kay, Clive S. Zent, Timothy G. Call, Susan L. Slager, Deborah A. Bowen, Susan M. Schwager & Grzegorz S. Nowakowski. (2010) Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia. Leukemia & Lymphoma 51:7, pages 1233-1240.
Read now
Deborah A. Bowen, Timothy G. Call, Tait D. Shanafelt, Neil E. Kay, Susan M. Schwager, Megan S. Reinalda, Kari G. Rabe, Susan L. Slager & Clive S. Zent. (2010) Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone. Leukemia & Lymphoma 51:4, pages 620-627.
Read now
Anders Österborg. (2010) Ofatumumab, a human anti-CD20 monoclonal antibody. Expert Opinion on Biological Therapy 10:3, pages 439-449.
Read now
Farrukh T. Awan, Amy J. Johnson, Rosa Lapalombella, Weihong Hu, Margaret Lucas, Beth Fischer & John C. Byrd. (2010) Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia. Leukemia & Lymphoma 51:1, pages 27-38.
Read now
Lukas Smolej. (2009) Modern concepts in the treatment of chronic lymphocytic leukemia. Hematology 14:5, pages 249-254.
Read now
Andrew R. Pettitt. (2008) Glucocorticoid-based combination therapy for chronic lymphotic leukemia: new tricks for an old dog. Leukemia & Lymphoma 49:10, pages 1843-1845.
Read now
J. P. Quinn, S. Mohamedbhai, K. Chipperfield, M. Treacy, S. D'Sa & A. C. Nathwani. (2008) Efficacy of rituximab in combination with steroids in refractory chronic lymphocytic leukemia. Leukemia & Lymphoma 49:10, pages 1995-1998.
Read now

Articles from other publishers (55)

Xiaoqing Liu, Wenjing Yi, Baohang Xi & Qi Dai. (2022) Identification of Drug-Disease Associations Using a Random Walk with Restart Method and Supervised Learning. Computational and Mathematical Methods in Medicine 2022, pages 1-10.
Crossref
Ana Vagos Mata, Eduardo Espada, Daniela Alves, Blanca Polo, Maria João Costa, Conceição Lopes, João F. Lacerda & João Raposo. (2021) Chronic lymphocytic leukaemia/small lymphocytic lymphoma treatment with rituximab and high‐dose methylprednisolone, revisited. Cancer Medicine 10:24, pages 8768-8776.
Crossref
Martin Šimkovič, Pavel Vodárek, Monika Motyčková, Dominika Écsiová, Petra Rozsívalová, Heidi Móciková, Pavla Štěpánková, Alice Sýkorová, Kateřina Hrochová, Filip Vrbacký, David Belada, Pavel Žák & Lukáš Smolej. (2020) Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic Leukaemia. European Journal of Clinical Investigation 51:4.
Crossref
Bartosz Puła, Monika Długosz-Danecka, Aleksander Salomon-Perzyński, Agnieszka Szymczyk, Edyta Subocz, Bożena Katarzyna Budziszewska, Justyna Rybka, Lidia Gil, Anna Waszczuk-Gajda, Elżbieta Iskierka-Jażdżewska, Jan M. Zaucha, Michał Osowiecki, Weronika Piszczek, Paweł Steckiewicz, Łukasz Szukalski, Marek Hus, Ewa Lech-Marańda, Wojciech Jurczak & Krzysztof Jamroziak. (2020) Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors. Advances in Medical Sciences 65:2, pages 371-377.
Crossref
Farrukh T. Awan & John C. Byrd. 2020. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology 1850 1871.e5 .
Regina Pileckyte, Vilma Valceckiene, Mindaugas Stoskus, Reda Matuzeviciene, Jurgita Sejoniene, Tadas Zvirblis & Laimonas Griskevicius. (2019) Dose Intensive Rituximab and High-Dose Methylprednisolone in Elderly or Unfit Patients with Relapsed Chronic Lymphocytic Leukemia. Medicina 55:11, pages 719.
Crossref
Tadeusz Robak. 2019. Chronic Lymphocytic Leukemia. Chronic Lymphocytic Leukemia 107 119 .
Clark W. Distelhorst. (2018) Targeting Bcl-2-IP3 receptor interaction to treat cancer: A novel approach inspired by nearly a century treating cancer with adrenal corticosteroid hormones. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1865:11, pages 1795-1804.
Crossref
Krzysztof Warzocha, Marta Fidecka, Grzegorz Mazur, Daria Zawirska & Magdalena Piotrowska. (2017) Nieinterwencyjne badanie oceniające odpowiedź na leczenie u pacjentów z przewlekłą białaczką limfocytową (CLL) w zależności od zastosowanego schematu rytuksymab-chemioterapia. Acta Haematologica Polonica 48:4, pages 357-363.
Crossref
Bradley Heraly & Vicki A. Morrison. (2015) How I treat chronic lymphocytic leukemia in older patients. Journal of Geriatric Oncology 6:5, pages 333-340.
Crossref
Michael Doubek, Yvona Brychtova, Anna Panovska, Ludmila Sebejova, Olga Stehlikova, Jana Chovancova, Jitka Malcikova, Jana Smardova, Karla Plevova, Pavlina Volfova, Martin Trbusek, Marek Mraz, Denisa Bakesova, Jakub Trizuljak, Marketa Hadrabova, Petra Obrtlikova, Josef Karban, Lukas Smolej, Alexandra Oltova, Eva Jelinkova, Sarka Pospisilova & Jiri Mayer. (2015) Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study. American Journal of Hematology 90:5, pages 417-421.
Crossref
Fabienne McClanahan & John Gribben. (2014) Transplantation in Chronic Lymphocytic Leukemia. Hematology/Oncology Clinics of North America 28:6, pages 1055-1071.
Crossref
Polina Shindiapina, Jennifer R. Brown & Alexey V. Danilov. (2014) A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53 . British Journal of Haematology 167:2, pages 149-161.
Crossref
John C. Byrd & Joseph M. Flynn. 2014. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology 1958 1978.e7 .
T Prezma, A Shteinfer, L Admoni, Z Raviv, I Sela, I Levi & V Shoshan-Barmatz. (2013) VDAC1-based peptides: novel pro-apoptotic agents and potential therapeutics for B-cell chronic lymphocytic leukemia. Cell Death & Disease 4:9, pages e809-e809.
Crossref
Ohad Benjamini, Alessandra Ferrajoli & Michael J Keating. (2013) Approach to frontline therapy in elderly chronic lymphocytic leukemia patients. Aging Health 9:3, pages 331-347.
Crossref
Anna Panovská, Lukáš Smolej, Daniel Lysák, Yvona Brychtová, Martin Šimkovič, Monika Motyčková, Pavel Vodárek, Michaela Lindtnerová, Martin Trbušek, Jitka Malčíková, Šárka Pospíšilová, Jiří Mayer & Michael Doubek. (2013) The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab. European Journal of Haematology 90:6, pages 479-485.
Crossref
Carlo Visco, Silvia Finotto, Fabrizio Pomponi, Roberto Sartori, Francesco Laveder, Livio Trentin, Rossella Paolini, Eros Di Bona, Marco Ruggeri & Francesco Rodeghiero. (2013) The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high‐risk patients with chronic lymphocytic leukemia. American Journal of Hematology 88:4, pages 289-293.
Crossref
Xavier C. BadouxMichael J. KeatingSijin WenWilliam G. WierdaSusan M. O'BrienStefan FaderlRachel SargentJan A. BurgerAlessandra Ferrajoli. (2013) Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia. Journal of Clinical Oncology 31:5, pages 584-591.
Crossref
Martin Trbusek & Jitka Malcikova. 2013. Advances in Chronic Lymphocytic Leukemia. Advances in Chronic Lymphocytic Leukemia 109 131 .
Gautam Borthakur & Susan O’Brien. 2013. Neoplastic Diseases of the Blood. Neoplastic Diseases of the Blood 103 119 .
Kang Lu & Xin Wang. (2012) Therapeutic advancement of chronic lymphocytic leukemia. Journal of Hematology & Oncology 5:1.
Crossref
Maria Joao Baptista, Ana Muntañola, Eva Calpe, Pau Abrisqueta, Olga Salamero, Eva Fernández, Carles Codony, Eva Giné, Susana G. Kalko, Marta Crespo & Francesc Bosch. (2012) Differential Gene Expression Profile Associated to Apoptosis Induced by Dexamethasone in CLL Cells According to IGHV/ZAP-70 Status. Clinical Cancer Research 18:21, pages 5924-5933.
Crossref
Lukáš Smolej, Michael Doubek, Anna Panovská, Martin Šimkovič, Yvona Brychtová, David Belada, Monika Motyčková & Jiří Mayer. (2012) Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia. Leukemia Research 36:10, pages 1278-1282.
Crossref
M A Kharfan-Dabaja, J Pidala, A Kumar, T Terasawa & B Djulbegovic. (2012) Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis. Bone Marrow Transplantation 47:9, pages 1164-1170.
Crossref
D E Spaner. (2011) Oral high-dose glucocorticoids and Ofatumumab in fludarabine-resistant Chronic Lymphocytic Leukemia. Leukemia 26:5, pages 1144-1145.
Crossref
Tadeusz Robak. (2012) Przeciwciała monoklonalne w leczeniu przewlekłej białaczki limfocytowej. Acta Haematologica Polonica 43:2, pages 99-106.
Crossref
Tait D. Shanafelt, Neil E. Kay, Kari G. Rabe, David J. Inwards, Clive S. Zent, Jose F. Leis, Susan M. Schwager, Carrie A. Thompson, Deborah A. Bowen, Thomas E. Witzig, Susan L. Slager & Timothy G. Call. (2011) Hematologist/oncologist disease‐specific expertise and survival: Lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Cancer 118:7, pages 1827-1837.
Crossref
Marays VelizJavier Pinilla-Ibarz. (2012) Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia. Cancer Control 19:1, pages 37-53.
Crossref
Jonathan A. Gutman, Kelly M. Smith, John M. Pagel & John M. Pagel. 2012. Leukemia and Related Disorders. Leukemia and Related Disorders 67 96 .
Jennifer R. Brown. (2011) The Treatment of Relapsed Refractory Chronic Lymphocytic Leukemia. Hematology 2011:1, pages 110-118.
Crossref
Jason K. Molitoris, Karen S. McColl, Sarah Swerdlow, Mieko Matsuyama, Minh Lam, Terri H. Finkel, Shigemi Matsuyama & Clark W. Distelhorst. (2011) Glucocorticoid Elevation of Dexamethasone-induced Gene 2 (Dig2/RTP801/REDD1) Protein Mediates Autophagy in Lymphocytes. Journal of Biological Chemistry 286:34, pages 30181-30189.
Crossref
Alma Zecevic, Deepa Sampath, Brett Ewald, Rong Chen, William Wierda & William Plunkett. (2011) Killing of Chronic Lymphocytic Leukemia by the Combination of Fludarabine and Oxaliplatin Is Dependent on the Activity of XPF Endonuclease. Clinical Cancer Research 17:14, pages 4731-4741.
Crossref
Saman Hewamana & Claire Dearden. (2011) Treatment options for high-risk chronic lymphocytic leukaemia. Therapeutic Advances in Hematology 2:3, pages 147-159.
Crossref
Xavier C. Badoux, Michael J. Keating & William G. Wierda. (2010) What is the Best Frontline Therapy for Patients with CLL and 17p Deletion?. Current Hematologic Malignancy Reports 6:1, pages 36-46.
Crossref
Gillian M. Keating. (2011) Spotlight on Rituximab in Chronic Lymphocytic Leukemia, Low-Grade or Follicular Lymphoma, and Diffuse Large B-Cell Lymphoma†. BioDrugs 25:1, pages 55-61.
Crossref
Karen W. L. Yee & Susan M. O'Brien. 2011. Management of Hematologic Malignancies. Management of Hematologic Malignancies 81 102 .
Tait D. Shanafelt, Kari G. Rabe, Neil E. Kay, Clive S. Zent, Diane F. Jelinek, Megan S. Reinalda, Susan M. Schwager, Debbie A. Bowen, Susan L. Slager, Curtis A. Hanson & Timothy G. Call. (2010) Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. Cancer 116:20, pages 4777-4787.
Crossref
Gillian M. Keating. (2010) Rituximab. Drugs 70:11, pages 1445-1476.
Crossref
Tadeusz RobakAnna DmoszynskaPhilippe Solal-CélignyKrzysztof WarzochaJavier LoscertalesJohn CatalanoBoris V. AfanasievLoree LarrattChristian H. GeislerMarco MontilloIlya ZyuzginPeter S. GanlyCaroline DartigeasAndrás RostaJörg MaurerMyriam MendilaM. Wayne SavilleNancy ValenteMichael K. WengerSergey I. Moiseev. (2010) Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia. Journal of Clinical Oncology 28:10, pages 1756-1765.
Crossref
Javier Pinilla-Ibarz & Amy Mcquary. (2010) Chronic Lymphocytic Leukemia: Putting New Treatment Options into Perspective. Cancer Control 17:2_suppl, pages 4-15.
Crossref
Samantha M. Jaglowski & John C. Byrd. (2010) Rituximab in Chronic Lymphocytic Leukemia. Seminars in Hematology 47:2, pages 156-169.
Crossref
Clive S. Zent & Neil E. Kay. (2010) Autoimmune Complications in Chronic Lymphocytic Leukaemia (CLL). Best Practice & Research Clinical Haematology 23:1, pages 47-59.
Crossref
Lukáš Smolej. (2010) How I Treat Elderly or Comorbid Patients with Chronic Lymphocytic Leukemia. Acta Medica (Hradec Kralove, Czech Republic) 53:4, pages 213-220.
Crossref
Tadeusz Robak, Krzysztof Jamroziak & Pawel Robak. (2009) Current and Emerging Treatments for Chronic Lymphocytic Leukaemia. Drugs 69:17, pages 2415-2449.
Crossref
Emeline De Viron, Laurent Knoops, Thierry Connerotte, Caroline Smal, Lucienne Michaux, Pascale Saussoy, Pascal Vannuffel, Eline Beert, Marie‐Christiane Vekemans, Cédric Hermans, Françoise Bontemps & Eric Van Den Neste. (2009) Impaired up‐regulation of polo‐like kinase 2 in B‐cell chronic lymphocytic leukaemia lymphocytes resistant to fludarabine and 2‐chlorodeoxyadenosine: a potential marker of defective damage response. British Journal of Haematology 147:5, pages 641-652.
Crossref
Ashley E. Glode & Anthony JarkowskiIIIIII. (2012) Bendamustine: A New Treatment Option for Chronic Lymphocytic Leukemia. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 29:11, pages 1375-1384.
Crossref
J E Castro, D F James, J D Sandoval-Sus, S Jain, J Bole, L Rassenti & T J Kipps. (2009) Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia 23:10, pages 1779-1789.
Crossref
Marina Motta, William G. Wierda & Alessandra Ferrajoli. (2009) Chronic lymphocytic leukemia. Cancer 115:17, pages 3830-3841.
Crossref
Constantine S. TamTait D. ShanafeltWilliam G. WierdaLynne V. Abruzzo, Daniel L. Van Dyke, Susan O'BrienAlessandra FerrajoliSusan A. LernerAlice LynnNeil E. KayMichael J. Keating. (2009) De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood 114:5, pages 957-964.
Crossref
Tait D. Shanafelt, Neil E. Kay, Greg Jenkins, Timothy G. Call, Clive S. Zent, Diane F. Jelinek, William G. Morice, Justin Boysen, Liam Zakko, Susan Schwager, Susan L. Slager & Curtis A. Hanson. (2009) B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood 113:18, pages 4188-4196.
Crossref
S Faderl, A Ferrajoli, O Frankfurt & A Pettitt. (2008) Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy. Leukemia 23:3, pages 457-466.
Crossref
Tait D. Shanafelt, Greg Jenkins, Timothy G. Call, Clive S. Zent, Susan Slager, Deborah A. Bowen, Susan Schwager, Curtis A. Hanson, Diane F. Jelinek & Neil E. Kay. (2009) Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer 115:2, pages 363-372.
Crossref
Tait D. Shanafelt. (2009) Predicting clinical outcome in CLL: how and why. Hematology 2009:1, pages 421-429.
Crossref
. (2008) Current Awareness in Hematological Oncology. Hematological Oncology 26:3, pages 184-191.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.